1. Clinical Application of New CV Outcomes Data

3. Program Goals

4. Diabetes as a CV Risk Equivalent

5. The Need for CV Outcomes Studies

6. DPP-4 Inhibitors Mechanism of Action

7. SAVOR, EXAMINE, and TECOS Baseline Characteristics

8. SAVOR: Primary End Point

9. SAVOR: Secondary End Point

10. EXAMINE: Primary End Point

11. EXAMINE Primary End Point by Components

12. TECOS: Primary Composite CV Outcome Intent-to-Treat Analysis for Superiority

13. TECOS: Secondary Composite CV Outcome Intent-to-Treat Population

14. TECOS, EXAMINE, and SAVOR Hospitalization for HF

15. Ongoing CAROLINA and CARMELINA Trials

16. GLP-1 Receptor Agonists Mechanism of Action

18. Lixisenatide*

19. ELIXA Study Design

22. ELIXA No CV Risks of Benefits

23. Ongoing GLP-1 Receptor Agonist CV Outcomes Studies

24. SGLT2 Inhibitors Mechanism of Action

25. EMPA-REG OUTCOME® Study Design

26. EMPA-REG OUTCOME® Baseline Characteristics

27. EMPA-REG OUTCOME® Baseline CV Characteristics

28. EMPA-REG OUTCOME® HbA1c After 12 Weeks

31. All-cause mortality

32. All-cause mortality

34. EMPA-REG OUTCOME® Adverse Effects

35. Ongoing SGLT2 Inhibitor CV Outcomes Studies